scholarly journals High mobility group box 1 as a biomarker in critically ill patients

2018 ◽  
Vol 32 (8) ◽  
pp. e22584 ◽  
Author(s):  
Eray Yagmur ◽  
Lukas Buendgens ◽  
Ulf Herbers ◽  
Anne Beeretz ◽  
Ralf Weiskirchen ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
High Mobility ◽  
High Mobility Group

scholarly journals High Mobility Group Box-1 Protein and Outcomes in Critically Ill Surgical Patients Requiring Open Abdominal Management

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Michelle S. Malig ◽  
Craig N. Jenne ◽  
Chad G. Ball ◽  
Derek J. Roberts ◽  
Zhengwen Xiao ◽  
...  
Keyword(s):  
Critically Ill ◽  
Controlled Trial ◽  
Clinical Care ◽  
High Mobility ◽  
Abdominal Sepsis ◽  
High Mobility Group ◽  
Molecular Patterns ◽  
Injured Patients ◽  
Relationship Of ◽  
Damage Associated Molecular Patterns

Background. Previous studies assessing various cytokines in the critically ill/injured have been uninformative in terms of translating to clinical care management. Animal abdominal sepsis work suggests that enhanced intraperitoneal (IP) clearance of Damage-Associated Molecular Patterns (DAMPs) improves outcome. Thus measuring the responses of DAMPs offers alternate potential insights and a representative DAMP, High Mobility Group Box-1 protein (HMGB-1), was considered. While IP biomediators are being recognized in critical illness/trauma, HMGB-1 behaviour has not been examined in open abdomen (OA) management. Methods. A modified protocol for HMGB-1 detection was used to examine plasma/IP fluid samples from 44 critically ill/injured OA patients enrolled in a randomized controlled trial comparing two negative pressure peritoneal therapies (NPPT): Active NPPT (ANPPT) and Barker’s Vacuum Pack NPPT (BVP). Samples were collected and analyzed at the time of laparotomy and at 24 and 48 hours after. Results. There were no statistically significant differences in survivor versus nonsurvivor HMGB-1 plasma or IP concentrations at baseline, 24 hours, or 48 hours. However, plasma HMGB-1 levels tended to increase continuously in the BVP cohort. Conclusions. HMGB-1 appeared to behave differently between NPPT cohorts. Further studies are needed to elucidate the relationship of HMGB-1 and outcomes in septic/injured patients.

scholarly journals High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as Biomarkers in Critically Ill COVID-19 Patients

2021 ◽  
Author(s):  
Chaisith Sivakorn ◽  
Jutamas Dechsanga ◽  
Lawan Jamjumrus ◽  
Kobporn Boonnak ◽  
Marcus J. Schultz ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Critically Ill ◽  
Sofa Score ◽  
Interleukin 6 ◽  
Plasma Levels ◽  
High Mobility ◽  
High Mobility Group ◽  
Icu Mortality ◽  
Icu Admission

Exuberant inflammation manifesting as a “cytokine storm” has been suggested as a central feature in the pathogenesis of severe coronavirus disease 2019 (COVID-19). This study investigated two prognostic biomarkers, the high mobility group box 1 (HMGB1) and interleukin-6 (IL-6), in patients with severe COVID-19 at the time of admission in the intensive care unit (ICU). Of 60 ICU patients with COVID-19 enrolled and analyzed in this prospective cohort study, 48 patients (80%) were alive at ICU discharge. HMGB1 and IL-6 plasma levels at ICU admission were elevated compared with a healthy control, both in ICU nonsurvivors and ICU survivors. HMGB1 and IL-6 plasma levels were higher in patients with a higher Sequential Organ Failure Assessment (SOFA) score (> 10), and the presence of septic shock or acute kidney injury. HMGB1 and IL-6 plasma levels were also higher in patients with a poor oxygenation status (PaO2/FiO2 < 150 mm Hg) and a longer duration of ventilation (> 7 days). Plasma HMGB1 and IL-6 levels at ICU admission also correlated with other prognostic markers, including the maximum neutrophil/lymphocyte ratio, D-dimer levels, and C-reactive protein levels. Plasma HMGB1 and IL-6 levels at ICU admission predicted ICU mortality with comparable accuracy to the SOFA score and the COVID-GRAM risk score. Higher HMGB1 and IL-6 were not independently associated with ICU mortality after adjustment for age, gender, and comorbidities in multivariate analysis models. In conclusion, plasma HMGB1 and IL6 at ICU admission may serve as prognostic biomarkers in critically ill COVID-19 patients.

scholarly journals Different Biomarker Kinetics in Critically Ill Patients with High Lactate Levels

Diagnostics ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 454
Author(s):  
Ryo Matsuura ◽  
Yohei Komaru ◽  
Yoshihisa Miyamoto ◽  
Teruhiko Yoshida ◽  
Kohei Yoshimoto ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Reduction Rate ◽  
High Mobility ◽  
Icu Mortality ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Surgical Icu ◽  
Lactate Levels ◽  
Neutrophil Gelatinase ◽  
Kinetics Of

We evaluated the association of the kinetics of interleukin-6 (IL-6), neutrophil gelatinase-associated lipocalin (NGAL), and high-mobility group box 1 (HMGB1) with intensive care unit (ICU) mortality in critically ill patients with hyperlactatemia. This proof-of-concept study was conducted with prospectively enrolled patients admitted to a medical/surgical ICU with hyperlactatemia (lactate levels >4 mmol/L). Blood lactate, IL-6, NGAL, and HMGB1 were measured every 2 h until 6 h post ICU admission. The primary outcome was ICU mortality. Of thirty patients in this study, 14 patients (47%) had sepsis, and the ICU mortality was 47%. IL-6 and NGAL levels were significantly higher in septic patients than in non-septic patients. On kinetic analysis, the lactate levels were significantly decreased in survivors, and the NGAL levels were significantly increased in non-survivors. Among septic patients, a decline in IL-6 levels were observed in survivors. The HMGB1 levels were unchanged in survivors and non-survivors regardless of sepsis complication. Non-septic patients with higher reduction rate of lactate and HMGB1 had the lowest mortality than the others. ICU patients exhibited different kinetic patterns in lactate, NGAL, and IL-6, but HMGB1 did not seem to change over the 6-h duration. Further studies are necessary to evaluate the efficacy of the combination of the inflammatory biomarkers with lactate.

Sign in / Sign up

Export Citation Format

Share Document